Search
Search
Close this search box.
Search
Close this search box.

Medtronic Infuse Settlement

Leading Justice Seal

$22 Million Settlement Agreement Reached in Medtronic Infuse Lawsuit

Close to 1,000 Infuse bone graft lawsuits will be resolved per Medtronic’s recent $22 million settlement agreement.

Medical device maker Medtronic has agreed to pay about $22 million to resolve approximately 950 Infuse lawsuits filed on behalf of patients across the country who have suffered complications allegedly associated with the bone graft product. The Medtronic Infuse agreement was announced in a press release on May 6, but the significant settlement still leaves an estimated 750 product liability cases unresolved. If you believe you have been adversely affected by side effects of Medtronic Infuse bone graft product, contact an experienced Infuse spine attorney today to discuss your legal options. You may have grounds to file a product liability lawsuit against Medtronic, in order to pursue financial compensation for your injuries and medical expenses.

Medtronic Marketed Infuse for Off-Label Uses

Medtronic Infuse is a relatively new type of bio-engineered bone graft device that has been marketed by the manufacturing company as an alternative to traditional spine fusions, where bone is harvested from a cadaver or another part of the patient’s body. The Infuse bone graft product has been approved by the U.S. Food and Drug Administration (FDA) for limited use with an “LT Cage” during certain spinal fusion procedures, to encourage bone growth and fuse the gaps between vertebrae. However, Medtronic has been accused of illegally marketing Infuse for uses not approved by the FDA, raising concerns about the safety and effectiveness of the company’s controversial bone growth product.

Infuse Health Risks Withheld from Consumers

According to allegations raised in Medtronic Infuse lawsuits, the medical device maker has concealed important safety information from consumers about the risks associated with off-label uses of the bone graft product. Despite repeated attempts by Medtronic to have the Infuse cases filed against the company dismissed since the controversial product was approved by the FDA, plaintiffs argue that Medtronic’s decision to promote Infuse for off-label uses prevents the company from being protected by the Supreme Court decision in Riegel v. Medtronic, which allows for state-law product liability claims involving medical devices to be preempted by federal law.

Consult a Medtronic Infuse Lawyer Today

In March 2014, Medtronic estimated that the number of Infuse lawsuits filed against the manufacturing company will continue to grow considerably, as more information comes to light about the serious risks associated with the bone graft product. If you have been implanted with Medtronic’s Infuse device, and you have since suffered complications like chronic pain, uncontrolled bone growth, nerve injuries, or difficulty swallowing, breathing or speaking, our consumer advocates at the Leading Justice can help. We are dedicated to protecting the rights of consumers harmed by dangerous or defective medical devices, and can put you in touch with a lawyer who has experience handling Medtronic Infuse claims.

author avatar
Andrew Sarski
Facebook
Twitter
Pinterest
LinkedIn
Reddit
WhatsApp

Related Posts

CooperSurgical Sues Third-Party Lab, Alleging Inadequate Testing of Recalled Embryo Solution

Allegations have surfaced that a third-party testing lab failed to follow proper procedures and misrepresented the results of quality assurance testing on CooperSurgical’s embryo culture solution, leading to a costly recall and devastating consequences for affected patients. CooperSurgical is suing the Massachusetts-based lab, known as Embryotech, stating that it has

Nearly 11,000 Suboxone Lawsuits Allege Dental Damage from Opioid Addiction Treatment

The opioid crisis has ravaged communities across the United States, leaving countless individuals and families grappling with the devastating consequences of addiction. In response, healthcare providers have increasingly turned to medications like Suboxone to aid in opioid use disorder (OUD) treatment and withdrawal management. However, a growing number of Suboxone

Avon Ordered to Pay $24.4M in Talcum Powder Mesothelioma Trial

An Illinois jury has delivered a $24.4 million verdict in the latest talcum powder cancer trial, finding that cosmetics manufacturer Avon Products Inc. should have known its talc-based products were contaminated with asbestos. The verdict, returned in a complaint brought by a janitor diagnosed with pleural mesothelioma in 2023, decades

Scroll to Top